# US 2004/0082504 A1 · Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082504 A1
- Document ID: US20040082504A1
- Status: Published application
- Kind: A1
- Application number: 10/435,319
- Filed: 2003-05-09
- Published: 2004-04-29
- Earliest claimed: 2002-05-10
- Inventors: Atul Varadhachary; Rick Barsky; Karel Petrak; Bert O'Malley
- Web page: https://patentgrep.com/patent/US20040082504A1

## CPC

- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A23L 33/19: Dairy proteins
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.

## Claims

### Claim 1

A method of treating a hyperproliferative disease comprising the step of administering intratumorally to a subject a lactoferrin composition in an amount sufficient to provide an improvement in the hyperproliferative disease in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said lactoferrin composition is dispersed in a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein said lactoferrin is mammalian lactoferrin.

### Claim 4 (depends on 3)

The method of claim 3, wherein said lactoferrin is human.

### Claim 5 (depends on 3)

The method of claim 3, wherein said lactoferrin is bovine.

### Claim 6 (depends on 3)

The method of claim 3, wherein said lactoferrin is recombinant lactoferrin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amount of the lactoferrin composition that is administered is about 0.1 μg to about 10 g per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hyperproliferative disease is further defined as cancer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer comprises a neoplasm.

### Claim 10 (depends on 9)

The method of claim 9, wherein the neoplasm is selected from the group consisting of melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, leukemia, neuroblastoma, squamous cell, head, neck, gum, tongue, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, sarcoma, cervical, gastrointestinal, lymphoma, brain, colon, and bladder.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hyperproliferative disease is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, and psoriasis.

### Claim 12

A method of treating a hyperproliferative disease comprising the step of supplementing a systemic immune system in a subject by increasing the amount of lactoferrin at the site of the hyperproliferative disease.

### Claim 13 (depends on 12)

The method of claim 12, wherein said lactoferrin is recombinant lactoferrin.

### Claim 14 (depends on 12)

The method of claim 12, wherein said lactoferrin is administered intratumorally.

### Claim 15 (depends on 12)

The method of claim 12, wherein said lactoferrin stimulates the production of interleukin-18.

### Claim 16 (depends on 12)

The method of claim 12, wherein said lactoferrin stimulates the production of GM-CSF.

### Claim 17

A method of treating a hyperproliferative disease comprising the step of supplementing the local immune system in a subject by increasing the amount of lactoferrin at the site of the hyperproliferative disease.

### Claim 18 (depends on 17)

The method of claim 17, wherein said lactoferrin is recombinant lactoferrin.

### Claim 19 (depends on 17)

The method of claim 17, wherein said lactoferrin is administered intratumorally.

### Claim 20 (depends on 17)

The method of claim 17, wherein said lactoferrin stimulates the production of interleukin-18.

### Claim 21 (depends on 20)

The method of claim 20, wherein interleukin-18 stimulates the production, maturation or activity of immune cells.

### Claim 22 (depends on 17)

The method of claim 17, wherein said lactoferrin stimulates the production of GM-CSF.

### Claim 23

A method of enhancing a local immune response in the vicinity of a tumor following the step of administering intratumorally to said subject a lactoferrin composition.

### Claim 24 (depends on 23)

The method of claim 23, wherein said lactoferrin is recombinant lactoferrin.

### Claim 25 (depends on 23)

The method of claim 23, wherein said lactoferrin composition stimulates interleukin-18 in the site of injection.

### Claim 26 (depends on 23)

The method of claim 23, wherein said lactoferrin composition stimulates GM-CSF in the site of injection.

### Claim 27 (depends on 25)

The method of claim 25, wherein interleukin-18 stimulates the production, maturation or activity of immune cells.

### Claim 28 (depends on 27)

The method of claim 27, wherein the immune cells are T lymphocytes or natural killer cells.

### Claim 29 (depends on 28)

The method of claim 28, wherein the T lymphocytes are selected from the group consisting of CD4+, CD8+ and CD3+ cells.

### Claim 30 (depends on 26)

The method of claim 26, wherein said GM-CSF stimulates the production, maturation or activity of immune cells.

### Claim 31 (depends on 30)

The method of claim 30, wherein the immune cells are dendritic or other antigen presenting cells.

### Claim 32 (depends on 23)

The method of claim 23, wherein said subject suffers from a hyperproliferative disease.

### Claim 33 (depends on 1)

The method of claim 1 further comprising additionally administering chemotherapy, immunotherapy, surgery, biotherapy, radiotherapy or a combination thereof.

### Claim 34

A method of treating a hyperproliferative disease comprising administering intratumorally to a subject a lactoferrin composition in combination with chemotherapy, biotherapy, immunotherapy, surgery or radiotherapy.
